ULTRAGENYX PHARMACEUTICAL INC. Capital Lease Obligations, Noncurrent
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Capital Lease Obligations, Noncurrent of $31.21 million as of 2019-09-30, per its 10-Q filed 2019-11-06.
Discontinued › Notes › Leases
us-gaap:CapitalLeaseObligationsNoncurrent · last filed 2019-11-06
- 2019-09-30: Capital Lease Obligations, Noncurrent $31.21M.
- 2019-06-30: Capital Lease Obligations, Noncurrent $32.97M.
- 2019-03-31: Capital Lease Obligations, Noncurrent $22.98M.
| Period end | Capital Lease Obligations, Noncurrent |
|---|---|
| 2019-09-30 | $31.21M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $32.97M 10-Q · filed 2019-08-02 |
| 2019-03-31 | $22.98M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |